Published in Mol Ther on November 11, 2008
RNA and disease. Cell (2009) 7.98
Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther (2009) 2.47
Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest (2010) 1.91
Identifying functional microRNAs in macrophages with polarized phenotypes. J Biol Chem (2012) 1.67
MicroRNA therapeutics. Gene Ther (2011) 1.61
Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system. BMC Neurosci (2010) 1.33
RNA viruses and the host microRNA machinery. Nat Rev Microbiol (2013) 1.31
The unstable repeats--three evolving faces of neurological disease. Neuron (2013) 1.26
Stable RNA interference rules for silencing. Nat Cell Biol (2014) 1.26
Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design. Gene Ther (2011) 1.22
Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer. Blood (2010) 1.21
Novel RNA-based strategies for therapeutic gene silencing. Mol Ther (2010) 1.20
Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. Biochim Biophys Acta (2011) 1.16
Sequence-non-specific effects of RNA interference triggers and microRNA regulators. Nucleic Acids Res (2009) 1.11
Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol Ther (2011) 1.09
Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease. Mol Ther (2009) 1.09
Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. Mol Ther (2012) 1.07
Gene networks and the neuroendocrine regulation of puberty. Mol Cell Endocrinol (2009) 1.06
Dicer-independent processing of short hairpin RNAs. Nucleic Acids Res (2013) 1.06
An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res (2011) 1.05
Design of small molecule-responsive microRNAs based on structural requirements for Drosha processing. Nucleic Acids Res (2010) 1.04
MicroRNAs as Molecular Targets for Cancer Therapy: On the Modulation of MicroRNA Expression. Pharmaceuticals (Basel) (2013) 1.04
Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa. EMBO Mol Med (2011) 1.02
A miR-21 hairpin structure-based gene knockdown vector. Biochem Biophys Res Commun (2010) 1.01
The dose can make the poison: lessons learned from adverse in vivo toxicities caused by RNAi overexpression. Silence (2011) 1.00
MicroRNAs and lung cancers: from pathogenesis to clinical implications. Front Med (2012) 1.00
RNAi medicine for the brain: progresses and challenges. Hum Mol Genet (2011) 1.00
An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation. PLoS One (2012) 0.99
Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles. Nucleic Acids Res (2009) 0.98
Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype. PLoS One (2009) 0.98
Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics. Hum Mol Genet (2009) 0.97
AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophy. Mol Ther (2011) 0.97
Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol Ther (2013) 0.96
Targeted delivery of mutant tolerant anti-coxsackievirus artificial microRNAs using folate conjugated bacteriophage Phi29 pRNA. PLoS One (2011) 0.96
Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. Hum Gene Ther (2014) 0.96
miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction. Mol Ther (2015) 0.94
Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol Ther (2013) 0.94
Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy. Mol Ther (2013) 0.94
RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1. Neurobiol Dis (2013) 0.94
siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse. Nucleic Acids Res (2012) 0.93
In vivo manipulation of gene expression in non-human primates using lentiviral vectors as delivery vehicles. Methods (2009) 0.92
The therapeutic potential of microRNAs in nervous system damage, degeneration, and repair. Neuromolecular Med (2009) 0.92
RNAi Therapeutic Platforms for Lung Diseases. Pharmaceuticals (Basel) (2013) 0.92
Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease. Mol Ther (2013) 0.91
Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model. Mol Ther (2012) 0.89
Lentiviral miR30-based RNA interference against heparanase suppresses melanoma metastasis with lower liver and lung toxicity. Int J Biol Sci (2013) 0.88
Viral envelope protein 53R gene highly specific silencing and iridovirus resistance in fish Cells by AmiRNA. PLoS One (2010) 0.87
A microRNA processing defect in smokers' macrophages is linked to SUMOylation of the endonuclease DICER. J Biol Chem (2014) 0.87
ADAM17 silencing by adenovirus encoding miRNA-embedded siRNA revealed essential signal transduction by angiotensin II in vascular smooth muscle cells. J Mol Cell Cardiol (2013) 0.86
Deriving four functional anti-HIV siRNAs from a single Pol III-generated transcript comprising two adjacent long hairpin RNA precursors. Nucleic Acids Res (2010) 0.86
Construction of HCC-targeting artificial miRNAs using natural miRNA precursors. Exp Ther Med (2013) 0.86
Embedding siRNA sequences targeting apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy. Mol Ther (2012) 0.86
A microRNA embedded AAV α-synuclein gene silencing vector for dopaminergic neurons. Brain Res (2011) 0.86
Development of small RNA delivery systems for lung cancer therapy. Int J Mol Sci (2015) 0.85
Altered Purkinje cell miRNA expression and SCA1 pathogenesis. Neurobiol Dis (2013) 0.85
Cytoplasmic RNA viruses as potential vehicles for the delivery of therapeutic small RNAs. Virol J (2013) 0.85
Targeting MicroRNAs in Cancer Gene Therapy. Genes (Basel) (2017) 0.85
A new plasmid-based microRNA inhibitor system that inhibits microRNA families in transgenic mice and cells: a potential new therapeutic reagent. Gene Ther (2016) 0.84
State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications. Discov Med (2014) 0.84
RNA interference for improving the outcome of islet transplantation. Adv Drug Deliv Rev (2010) 0.84
Emerging Role of miRNAs in the Drug Resistance of Gastric Cancer. Int J Mol Sci (2016) 0.84
Alleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys. Proc Natl Acad Sci U S A (2015) 0.84
Single nucleotide seed modification restores in vivo tolerability of a toxic artificial miRNA sequence in the mouse brain. Nucleic Acids Res (2014) 0.83
Cell type specific, traceable gene silencing for functional gene analysis during vertebrate neural development. Nucleic Acids Res (2011) 0.83
Gene therapy to treat cardiac arrhythmias. Nat Rev Cardiol (2015) 0.83
The potential clinical applications and prospects of microRNAs in lung cancer. Onco Targets Ther (2014) 0.82
Artificial mirtron-mediated gene knockdown: functional DMPK silencing in mammalian cells. RNA (2012) 0.82
Studies of efficacy and liver toxicity related to adeno-associated virus-mediated RNA interference. Hum Gene Ther (2013) 0.82
RNA polymerase III can drive polycistronic expression of functional interfering RNAs designed to resemble microRNAs. Nucleic Acids Res (2009) 0.82
Recent advances in RNA interference therapeutics for CNS diseases. Neurotherapeutics (2013) 0.81
Improved knockdown from artificial microRNAs in an enhanced miR-155 backbone: a designer's guide to potent multi-target RNAi. Nucleic Acids Res (2015) 0.81
Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects. Brain Res (2014) 0.81
Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy. Hum Mol Genet (2015) 0.80
Nucleic Acid-Based Therapy Approaches for Huntington's Disease. Neurol Res Int (2012) 0.80
Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver. Gene Ther (2013) 0.80
Synergistic inhibition of avian leukosis virus subgroup J replication by miRNA-embedded siRNA interference of double-target. Virol J (2015) 0.80
Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia. Hum Mol Genet (2015) 0.80
Blocking sense-strand activity improves potency, safety and specificity of anti-hepatitis B virus short hairpin RNA. EMBO Mol Med (2016) 0.80
Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates. Hum Gene Ther (2016) 0.79
RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration. PLoS One (2014) 0.79
Expression of multiple artificial microRNAs from a chicken miRNA126-based lentiviral vector. PLoS One (2011) 0.79
Multiplexing seven miRNA-Based shRNAs to suppress HIV replication. Mol Ther (2014) 0.79
Optimization and comparison of knockdown efficacy between polymerase II expressed shRNA and artificial miRNA targeting luciferase and Apolipoprotein B100. BMC Biotechnol (2012) 0.79
Optimization of Critical Hairpin Features Allows miRNA-based Gene Knockdown Upon Single-copy Transduction. Mol Ther Nucleic Acids (2014) 0.79
Lentiviral vector-mediated RNA silencing in the central nervous system. Hum Gene Ther Methods (2013) 0.79
Prediction of potent shRNAs with a sequential classification algorithm. Nat Biotechnol (2017) 0.79
Adeno-associated virus-mediated microRNA delivery and therapeutics. Semin Liver Dis (2015) 0.78
miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma. Clin Investig (Lond) (2011) 0.78
Cell-specific expression of artificial microRNAs targeting essential genes exhibit potent antitumor effect on hepatocellular carcinoma cells. Oncotarget (2015) 0.78
Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS. Adv Drug Deliv Rev (2016) 0.78
A novel artificial microRNA expressing AAV vector for phospholamban silencing in cardiomyocytes improves Ca2+ uptake into the sarcoplasmic reticulum. PLoS One (2014) 0.78
Cell- and region-specific miR30-based gene knock-down with temporal control in the rat brain. BMC Mol Biol (2010) 0.78
MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations. Biomark Insights (2016) 0.77
Genetic modification of mouse bone marrow by lentiviral vector-mediated delivery of hypoxanthine-Guanine phosphoribosyltransferase short hairpin RNA confers chemoprotection against 6-thioguanine cytotoxicity. Transplant Proc (2013) 0.77
Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo. BMC Cancer (2010) 0.77
Functional silencing of guanylyl cyclase/natriuretic peptide receptor-A by microRNA interference: analysis of receptor endocytosis. Int J Biochem Mol Biol (2013) 0.77
Viral delivery of shRNA to amygdala neurons leads to neurotoxicity and deficits in Pavlovian fear conditioning. Neurobiol Learn Mem (2015) 0.77
Mutation-independent rescue of a novel mouse model of Retinitis Pigmentosa. Gene Ther (2012) 0.77
mRNA trans-splicing in gene therapy for genetic diseases. Wiley Interdiscip Rev RNA (2016) 0.77
Bipartite vectors for co-expression of a growth factor cDNA and short hairpin RNA against an apoptotic gene. J Gene Med (2009) 0.77
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
The nuclear RNase III Drosha initiates microRNA processing. Nature (2003) 35.49
Asymmetry in the assembly of the RNAi enzyme complex. Cell (2003) 22.18
Functional siRNAs and miRNAs exhibit strand bias. Cell (2003) 19.15
The Microprocessor complex mediates the genesis of microRNAs. Nature (2004) 17.70
Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev (2003) 17.64
Nuclear export of microRNA precursors. Science (2003) 16.59
Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. Cell (2004) 13.51
Antiviral actions of interferons. Clin Microbiol Rev (2001) 13.06
Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA (2004) 11.52
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell (2002) 10.30
Gene silencing in mammals by small interfering RNAs. Nat Rev Genet (2002) 7.80
3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods (2006) 6.96
Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet (2003) 6.49
Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol (2006) 5.78
siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol (2002) 5.65
RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A (2005) 4.79
Ribonuclease activity and RNA binding of recombinant human Dicer. EMBO J (2002) 4.73
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med (2004) 4.63
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A (2008) 4.53
Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther (2002) 3.92
Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature (1997) 3.16
SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell (1995) 2.96
Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res (2006) 2.93
Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med (2005) 2.80
Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res (2007) 2.62
Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther (2005) 2.47
Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther (2008) 2.01
Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther (2006) 1.99
Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA (2008) 1.70
Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Mol Biol (2004) 1.56
Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann Neurol (2005) 1.44
RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol (2006) 6.81
siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol (2002) 5.65
Transvascular delivery of small interfering RNA to the central nervous system. Nature (2007) 5.21
RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A (2005) 4.79
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med (2004) 4.63
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A (2008) 4.53
The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. J Neurosci (2008) 3.62
Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A (2003) 3.00
Structure and activity of putative intronic miRNA promoters. RNA (2010) 2.50
Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther (2009) 2.47
Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med (2003) 2.43
MicroRNAs potentiate neural development. Neuron (2009) 2.25
Restoring Acid-sensing ion channel-1a in the amygdala of knock-out mice rescues fear memory but not unconditioned fear responses. J Neurosci (2008) 1.90
Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity (2003) 1.84
Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther (2008) 1.82
Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. J Virol (2002) 1.77
Targeted viral delivery of Cre recombinase induces conditional gene deletion in cardiovascular circuits of the mouse brain. Physiol Genomics (2004) 1.74
Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med (2009) 1.72
Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol Ther (2011) 1.72
Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA (2008) 1.70
Clarifying lysosomal storage diseases. Trends Neurosci (2011) 1.57
Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med (2009) 1.57
CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J Neurosci (2005) 1.57
Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J Neurosci (2005) 1.56
A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration. J Neurosci (2004) 1.56
Gene therapy for lysosomal storage diseases. Mol Ther (2006) 1.55
Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther (2009) 1.55
Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. J Neurosci (2005) 1.53
Diverse splicing patterns of exonized Alu elements in human tissues. PLoS Genet (2008) 1.52
Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha. J Virol (2003) 1.45
Adenosine deamination in human transcripts generates novel microRNA binding sites. Hum Mol Genet (2009) 1.43
Widespread establishment and regulatory impact of Alu exons in human genes. Proc Natl Acad Sci U S A (2011) 1.40
Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc Natl Acad Sci U S A (2002) 1.33
Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. J Neurosci (2006) 1.33
Connecdenn, a novel DENN domain-containing protein of neuronal clathrin-coated vesicles functioning in synaptic vesicle endocytosis. J Neurosci (2006) 1.33
Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res (2004) 1.27
Selective gene transfer to key cardiovascular regions of the brain: comparison of two viral vector systems. Hypertension (2002) 1.27
The transcription factor ATF4 promotes skeletal myofiber atrophy during fasting. Mol Endocrinol (2010) 1.23
Integration site choice of a feline immunodeficiency virus vector. J Virol (2006) 1.20
Rho GTPases modulate entry of Ebola virus and vesicular stomatitis virus pseudotyped vectors. J Virol (2009) 1.20
In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins. J Virol (2002) 1.16
Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Blood (2005) 1.14
Adeno-associated virus type 5: transduction efficiency and cell-type specificity in the primate retina. Hum Gene Ther (2003) 1.12
Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease. Mol Ther (2007) 1.11
Defining the pathway for Tat-mediated delivery of beta-glucuronidase in cultured cells and MPS VII mice. Mol Ther (2005) 1.10
Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol Ther (2011) 1.09
Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease. Mol Ther (2009) 1.09
Huntington's disease: progress toward effective disease-modifying treatments and a cure. Hum Mol Genet (2010) 1.05
Membrane topology of CLN3, the protein underlying Batten disease. FEBS Lett (2003) 1.04
Gene transfer to the nonhuman primate retina with recombinant feline immunodeficiency virus vectors. Hum Gene Ther (2002) 1.04
What does it take to bind CAR? Mol Ther (2005) 1.03
Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med (2013) 1.02
Toward therapy for DYT1 dystonia: allele-specific silencing of mutant TorsinA. Ann Neurol (2003) 1.00
RNAi medicine for the brain: progresses and challenges. Hum Mol Genet (2011) 1.00
Evolution of alternative splicing in primate brain transcriptomes. Hum Mol Genet (2010) 0.99
Large-scale analysis of exonized mammalian-wide interspersed repeats in primate genomes. Hum Mol Genet (2009) 0.99
In vivo SELEX for Identification of Brain-penetrating Aptamers. Mol Ther Nucleic Acids (2013) 0.98
Generation of hairpin-based RNAi vectors for biological and therapeutic application. Methods Enzymol (2012) 0.97
RNAi therapeutics for CNS disorders. Brain Res (2010) 0.97
Viral-mediated gene transfer to mouse primary neural progenitor cells. Mol Ther (2002) 0.97
Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol Ther (2013) 0.94
The lymphocytic choriomeningitis virus envelope glycoprotein targets lentiviral gene transfer vector to neural progenitors in the murine brain. Mol Ther (2005) 0.94
A knock-in reporter model of Batten disease. J Neurosci (2007) 0.94
RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1. Neurobiol Dis (2013) 0.94
Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease. Mol Ther (2012) 0.93
siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse. Nucleic Acids Res (2012) 0.93
Changes in expression of NMDA-NR1 receptor subunits in the rostral ventromedial medulla modulate pain behaviors. Pain (2010) 0.92
Sustained mobilization of endogenous neural progenitors delays disease progression in a transgenic model of Huntington's disease. Cell Stem Cell (2013) 0.91
Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease. Mol Ther (2013) 0.91
MiR-34a represses Numbl in murine neural progenitor cells and antagonizes neuronal differentiation. PLoS One (2012) 0.91
Gene therapy grows into young adulthood: special review issue. Hum Mol Genet (2011) 0.89
Plasmid-based RNA interference: construction of small-hairpin RNA expression vectors. Methods Mol Biol (2005) 0.89
CLN3 loss disturbs membrane microdomain properties and protein transport in brain endothelial cells. J Neurosci (2013) 0.88
Spatial variation of metal bioaccumulation in the hydrothermal vent mussel Bathymodiolus azoricus. Mar Environ Res (2008) 0.88
Impact of human interleukin-10 on vector-induced inflammation and early graft function in rat lung transplantation. Am J Respir Cell Mol Biol (2003) 0.87
Tripeptide probes for tripeptidyl protease I production via gene transfer. J Med Chem (2003) 0.87
Feline immunodeficiency virus vectors. Gene transfer to mouse retina following intravitreal injection. J Gene Med (2002) 0.86
Functional microRNAs and target sites are created by lineage-specific transposition. Hum Mol Genet (2013) 0.86
Altered Purkinje cell miRNA expression and SCA1 pathogenesis. Neurobiol Dis (2013) 0.85
Adenovirus serotype 30 fiber does not mediate transduction via the coxsackie-adenovirus receptor. J Virol (2002) 0.84
RNAi therapy for neurodegenerative diseases. Curr Top Dev Biol (2006) 0.84
Singles engage the RNA interference pathway. Cell (2012) 0.84
Adeno-associated virus type 5 reduces learning deficits and restores glutamate receptor subunit levels in MPS VII mice CNS. Mol Ther (2007) 0.84
Gene Silencing Mediated by siRNA-binding Fusion Proteins Is Attenuated by Double-stranded RNA-binding Domain Structure. Mol Ther Nucleic Acids (2012) 0.83
Towards therapy using RNA interference. Am J Pharmacogenomics (2004) 0.83
Gene transfer to the brain using feline immunodeficiency virus-based lentivirus vectors. Methods Enzymol (2002) 0.83
Human-specific microRNA regulation of FOXO1: implications for microRNA recognition element evolution. Hum Mol Genet (2013) 0.82
Widespread dispersal of cholera toxin subunit b to brain and spinal cord neurons following systemic delivery. Exp Neurol (2002) 0.82
Recent advances in RNA interference therapeutics for CNS diseases. Neurotherapeutics (2013) 0.81
Osmoregulation of ceroid neuronal lipofuscinosis type 3 in the renal medulla. Am J Physiol Cell Physiol (2010) 0.81
Optimization of feline immunodeficiency virus vectors for RNA interference. J Virol (2006) 0.80
Efficient delivery of RNA interference oligonucleotides to polarized airway epithelia in vitro. Am J Physiol Lung Cell Mol Physiol (2013) 0.80